Humanwell Healthcare (Group) Co. Ltd. has disclosed Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of pruritus.
Humanwell Healthcare (Group) Co. Ltd. has divulged P2X purinoceptor 7 (P2RX7; P2X7) antagonists reported to be useful for the treatment of pain, inflammatory, neurological and immunological disorders.
Humanwell Healthcare (Group) Co. Ltd. has described fused ring compounds acting as angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of disorders of the ovary and female reproductive tract, metabolic diseases, cardiovascular, eye, gastrointestinal, neurological, renal and respiratory disorders.
Humanwell Healthcare (Group) Co. Ltd. has divulged Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of pain, autoimmune disease and dermatological disorders.
KAT6A and its paralogue KAT6B are histone acetyltransferases whose overexpression is linked to poor prognosis in ER+/HER2- breast cancer and other types of tumors.
Humanwell Healthcare (Group) Co. Ltd. has identified cyclopeptides reported to be useful for the treatment of Acinetobacter infections, particularly A. baumannii infections.
Humanwell Healthcare (Group) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, rheumatoid arthritis, renal disorders, multiple sclerosis, alopecia areata, urticaria, psoriasis and chronic obstructive pulmonary disease (COPD), among others.
Humanwell Healthcare (Group) Co. Ltd. has developed new heterocyclic compounds acting as angiotensin AT2 receptor antagonists reported to be useful for the treatment of neuropathy and neuropathic pain.
Humanwell Healthcare (Group) Co. Ltd. has patented compounds acting a type-2 angiotensin II receptor (AGTR2; AT2) antagonists reported to be useful for the treatment of neuropathy and neuropathic pain.
Humanwell Healthcare (Group) Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of atopic dermatitis, autoimmune disease, cancer, Crohn’s disease, psoriasis and ulcerative colitis.
